# The Trendlines Group Investing for change: Food and Health

Steve Rhodes Chair and CEO Todd Dollinger Chair and CEO Haim Brosh Chief Financial Officer

September 2021



### Legal disclaimer

#### Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.





We invest in innovations in **food** and **health**, leveraging our **experience**, **network**, **and resources** from seed to exit.







### Leadership



**Todd Dollinger, Chair and CEO** 

Trendlines' Founder with over 30 years of experience in bringing innovative products to market, from concept to exit



Steve Rhodes, Chair and CEO

Trendlines' Founder with over 30 years of rich experience and a deep understanding of the world of investing and building young companies



Haim Brosh, CFO

Over 25 years of managerial and financial experience in public and private companies



Nir Goldenberg, CEO Trendlines Innovation Labs

Brings together deep technological knowledge with marketing and business insights



Barak Singer, CEO
Trendlines Investments Israel

Extensive investment knowledge & experience + strong managerial and business capabilities



Eric Loh, CEO Trendlines Medical Singapore

Over 30 years experience establishing companies and leading their development



Nitza Kardish, PhD, CEO, Trendlines Agrifood

Vast experience in food and agriculture technologies alongside strong business acumen



### Strategic partnerships for growth



Chairman Vincent Tchenguiz

- CBG provides non-regulated advisory services to Librae Holdings, Trendfood, and Agriline
- Librae Holdings is Trendlines' largest shareholder (23%)
- Trendfood has invested \$10M in the Trendlines Agrifood Fund
- Agriline has invested in 20+ of Trendlines' portfolio companies



- Investor and acquirer of Trendlines' portfolio companies
- Partner with Trendlines Innovation Labs



- Venture fund with Trendlines for innovative agrifood investing
- Fund has so far invested in three companies
- Informed consultation on all things agrifood





### The natural food color revolution

A broad-spectrum of healthy plant-based colors produced via fermentation technology, using baker's yeast as a biofactory. Phytolon's high-quality and cost-effective pigments offer value for

consumers, the environment and food industry.

#### **Achievements**

- Full POC: color production & food application
- Market focus verified from industry leaders
- Pilot projects at global food industry leaders including Nestlé

- Last investment round: US\$4.6 million
- Trendlines' investment to date: US\$1.1 million
- Trendlines' holdings: 69%



Plant-based colors produced via costeffective and sustainable fermentation of yeast









Founded 2018



CEO Halim Jubran, PhD



**IP** licensed from
Weizmann institute of
Science



Funding US\$5.8 million



**Investors** Millennium Food-Tech, EIT-Food, Mori Arkin, CBG











- Strategic service agreement
- Collaboration with strategic partners



First commercial grasshopper farm in the world

- Joint development with a large food company
- Alternative protein for food producers

### FruitSpec.

Early-stage prediction of crop yields in orchards and vines

- Sales in the United States, South America, Israel and South Africa
- Strategic investors from China and South Africa



Orally-administered disease prevention for shrimp and fish

• Strategic investors:









### Robotic external fixation with real-time feedback

A robotic, digitally enabled external fixation system for orthopedic treatments that allows real-time physician follow-up and reduces dependency on patient compliance

#### **Achievements**

- Successful FIH in US and Israel
- Received FDA clearance
- Completed two investment rounds led by J&J innovation



The OrthoSpin strut and control box are part of a smart external fixation system

- Last investment round: US\$5 million
- Trendlines' investment to date: US\$2.3 million
- Trendlines' holdings: 27%









Founded 2014



**CEO** Oren Cohen **Chair** Assaf Dekel, MD



**IP** 1 National phase (U.S., EU, China); 1 provisional



**Funding** US\$8 million



Investors
Trendlines,
J&J Innovation













Meniscus repair system

- FDA and CE clearance
- Launched commercial sales in U.S.



Removable stent following sinus surgery

- Began sales in US
- FDA clearance



Digital home dialysis

- **FDA** clearance in process
- 2<sup>nd</sup> clinical trial underway



Drug/device combination for the treatment of bladder diseases

• Strategic partnership with large pharma company






Low-profile Percutaneous Endoscopic Gastrostomy (PEG) device for enteral feeding

- FDA clearance
- Strategic investors from Germany and China
- Launching commercial sales





### Portfolio value expansion






## Book value vs. guaranteed exit value




■ Trendlines' exit value, not including earnouts and royalties





## The value opportunity gap

The value opportunity gap compares our consistent increase in portfolio values with our share price.





# Key financial developments

	30 June 2021	<b>31 December 2020</b>
Portfolio value	US\$92.1 million	US\$83.7 million
Total equity	US\$100.5 million	US\$96.3 million
NAV per share	US\$0.13; S\$0.17	US\$0.12; S\$0.16
	H1 2021	H1 2020
Net gain/(loss)	US\$4.1 million	(US\$4.1 million)



### 2021 to date

LOI

Letter of intent for acquisition of portfolio company by a public corporation

Regulatory clearance





FDA for G2 device

CE mark

Selected raises and partnerships









US\$7.5 million

US\$4.3 million

US\$2.2 million



Clinical & field trials

















# We invest in food and health innovation to impact lives

locations: Israel • Singapore • China

years' investment and company building experience

portfolio companies

advanced-stage companies

\$307 million raised for portfolio companies

Exits

8.7X return and 175% IRR on exits



# Creating and developing companies to improve the human condition

**SGX: 42T** 

**OTCQX: TRNLY** 

+972.72.260.7000 www.trendlines.com









Steve Rhodes, Chair & CEO steve@trendlines.com

Todd Dollinger, Chair & CEO todd@trendlines.com

Haim Brosh, Chief Financial Officer haim@trendlines.com

GENERAL ANNOUNCEMENT: PRESS RELEASE - INVESTOR PRESENTATION SEPTEMBER 2021 Issuer & Securities

Issuer/ Manager

THE TRENDLINES GROUP LTD.

THE TRENDLINES GROUP LTD. - IL0011328858 - 42T Stapled Security

Securities

Joint Company Secretary

Nο Announcement Details

Announcement Title General Announcement

Date & Time of Broadcast 02-Sep-2021 19:22:21 Status

New

Announcement Sub Title

Press release - Investor Presentation September 2021

Announcement Reference

SG210902OTHRI244

Submitted By (Co./ Ind. Name) Haim Brosh

Designation